{
    "qwen-v2.5-14b-instruct": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "qwen-v2.5-14b-instruct",
            "response": [
                "Imiquimod (IMQ)",
                "Vismodegib (SMO)",
                "Cetuximab (C225)",
                "Talimogene laherparepvec (T-VEC)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Ipilimumab (Yervoy)",
                "Vemurafenib (PLX4032)",
                "Dabrafenib (TAFINISIO)",
                "Trametinib (GSK1120212)",
                "Binimetinib (MEK162)",
                "Encorafenib (LGX818)",
                "Cobimetinib (CG-100649)",
                "Selumetinib (AZD6244)",
                "Braftovi (Encorafenib)",
                "Mektovi (Binimetinib)",
                "Talazoparib (BMN-673)",
                "Taselisib (GDC-0032)",
                "Alpelisib (BYL719)",
                "Atezolizumab (MPDL3280A)",
                "Durvalumab (MEDI4736)",
                "Avelumab (MSB0010718C)",
                "Trabectedin (Yondelis)"
            ]
        }
    ],
    "phi-v4": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "phi-v4",
            "response": [
                "Vismodegib (Erivedge)",
                "Sonidegib (Odomzo)",
                "Dabrafenib (Tafinlar)",
                "Trametinib (Mekinist)",
                "Vemurafenib (Zelboraf)",
                "Cobimetinib (Cotellic)",
                "Dacomitinib (Vizimpro)",
                "Binimetinib (Mektovi)",
                "Ametrine (combination of vemurafenib and cobimetinib)",
                "Encorafenib (Braftovi)",
                "Binimetinib (Mektovi) in combination with encorafenib",
                "Cetuximab (Erbitux)",
                "Paclitaxel (in combination with carboplatin)",
                "Doxorubicin (in combination with other drugs)",
                "Carboplatin (in combination with other drugs)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Cemiplimab (Libtayo)",
                "Atezolizumab (Tecentriq)",
                "Ipilimumab (Yervoy)",
                "Combination of ipilimumab and nivolumab",
                "Combination of pembrolizumab and cemiplimab",
                "Combination of dabrafenib and trametinib",
                "Combination of vemurafenib and cobimetinib"
            ]
        }
    ],
    "mistral-small-instruct-24B": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "mistral-small-instruct-24B",
            "response": [
                "Dacarbazine (DTIC)",
                "Temozolomide (TMZ)",
                "Cisplatin",
                "Carboplatin",
                "Vemurafenib",
                "Ipilimumab",
                "Nivolumab",
                "Pembrolizumab",
                "Atezolizumab",
                "Cemiplimab",
                "Lenvatinib",
                "Sorafenib",
                "Pembrolizumab",
                "Sonidegib",
                "Vismodegib",
                "Talimogene laherparepvec (T-VEC)",
                "Ibritumomab tiuxetan",
                "Avelumab",
                "Durvalumab",
                "Cobimetinib",
                "Trametinib",
                "Sunitinib",
                "Nivolumab",
                "Bempegaldesleukin"
            ]
        }
    ],
    "gemma-3": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "gemma-3",
            "response": [
                "5-Fluorouracil (5-FU)",
                "Imiquimod (Aldara)",
                "Retinoids (e.g., Tretinoin)",
                "Interferon alfa-2b (Intron A)",
                "Vismodegib (Erivedge)",
                "Sonidegib (Odomzo)",
                "Mohs Surgery (procedure using drugs for local anesthesia/hemostasis)",
                "Topical Bleomycin",
                "Photodynamic Therapy (with aminolevulinic acid)",
                "Fluorouracil cream (Efudex)",
                "Ingenol Mebutate (Picato)",
                "Diclofenac (Solaraze)",
                "Metimazole (Tapazole) - for cutaneous T-cell lymphoma",
                "Acitretin (Soriatane)",
                "Isotretinoin (Accutane)",
                "Bevacizumab (Avastin) - off-label use",
                "Cetuximab (Erbitux) - off-label use",
                "Pembrolizumab (Keytruda) - for advanced melanoma",
                "Nivolumab (Opdivo) - for advanced melanoma",
                "Binimetinib (Mektovi)",
                "Trametinib (Mekinist)",
                "Cobimetinib (Cotellic)",
                "Vemurafenib (Zelboraf)",
                "Dabrafenib (Tafinlar)"
            ]
        }
    ],
    "gpt-4o": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "gpt-4o",
            "response": [
                "Vemurafenib (PLX4032)",
                "Dabrafenib (GSK2118436)",
                "Trametinib (GSK1120212)",
                "Cobimetinib (GDC-0973)",
                "Binimetinib (MEK162)",
                "Encorafenib (LGX818)",
                "Pembrolizumab (MK-3475)",
                "Nivolumab (BMS-936558)",
                "Ipilimumab (MDX-010)",
                "Atezolizumab (MPDL3280A)",
                "Cemiplimab (REGN2810)",
                "Sonidegib (LDE225)",
                "Vismodegib (GDC-0449)",
                "Talimogene laherparepvec (T-VEC)",
                "Imiquimod (Aldara)",
                "Fluorouracil (5-FU)",
                "Methotrexate (MTX)",
                "Paclitaxel (Taxol)",
                "Docetaxel (Taxotere)",
                "Carboplatin (Paraplatin)",
                "Dacarbazine (DTIC)",
                "Temozolomide (Temodar)",
                "Avelumab (MSB0010718C)",
                "Cemiplimab-rwlc (Libtayo)"
            ]
        }
    ],
    "gpt-4o-mini": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "gpt-4o-mini",
            "response": [
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Dabrafenib (Tafinlar)",
                "Trametinib (Mekinist)",
                "Vemurafenib (Zelboraf)",
                "Imatinib (Gleevec)",
                "Atezolizumab (Tecentriq)",
                "Durvalumab (Imfinzi)",
                "Talimogene laherparepvec (T-VEC)",
                "Cemiplimab (Libtayo)",
                "Ertugliflozin (Steglatro)",
                "Sunitinib (Sutent)",
                "Sorafenib (Nexavar)",
                "Regorafenib (Stivarga)",
                "Lenvatinib (Lenvima)",
                "BRAF inhibitors",
                "MEK inhibitors",
                "Ipilimumab (Yervoy)",
                "Axitinib (Inlyta)",
                "Nintedanib (Ofev)",
                "Selumetinib (Koselugo)",
                "Cabozantinib (Cabometyx)",
                "Tazemetostat (Tazverik)",
                "Ruxolitinib (Jakafi)",
                "Brentuximab vedotin (Adcetris)"
            ]
        }
    ],
    "gpt-4-32k": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "gpt-4-32k",
            "response": [
                "Cetuximab (Erbitux)",
                "Dabrafenib (Tafinlar)",
                "Imiquimod (Aldara)",
                "Interferon (Intron A)",
                "Ipilimumab (Yervoy)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Vemurafenib (Zelboraf)",
                "Trametinib (Mekinist)",
                "Avelumab (Bavencio)",
                "Cobimetinib (Cotellic)",
                "Binimetinib (Mektovi)",
                "Encorafenib (Braftovi)",
                "Vismodegib (Erivedge)",
                "Sonomedin-C (Increlex)",
                "Peginterferon Alfa-2b (Sylatron)",
                "Interleukin-2 (Proleukin)",
                "Electroporation Therapy with Bleomycin (Electrochemotherapy)",
                "Vindesine (Eldisine)",
                "Mitomycin (Mutamycin)",
                "Paclitaxel (Taxol)",
                "Docetaxel (Taxotere)",
                "Fluorouracil (Efudex)",
                "Carboplatin (Paraplatin)"
            ]
        }
    ],
    "gpt-35-turbo-16k": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "gpt-35-turbo-16k",
            "response": [
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Ipilimumab (Yervoy)",
                "Atezolizumab (Tecentriq)",
                "Avelumab (Bavencio)",
                "Durvalumab (Imfinzi)",
                "Cemiplimab (Libtayo)",
                "Cobimetinib (Cotellic)",
                "Trametinib (Mekinist)",
                "Dabrafenib (Tafinlar)",
                "Vemurafenib (Zelboraf)",
                "Encorafenib (Braftovi)",
                "Binimetinib (Mektovi)",
                "Cobimetinib (Cotellic)",
                "Dabrafenib (Tafinlar)",
                "Vemurafenib (Zelboraf)",
                "Encorafenib (Braftovi)",
                "Binimetinib (Mektovi)",
                "Trametinib (Mekinist)",
                "Dabrafenib (Tafinlar)",
                "Vemurafenib (Zelboraf)",
                "Encorafenib (Braftovi)",
                "Binimetinib (Mektovi)"
            ]
        }
    ],
    "o1-mini": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "o1-mini",
            "response": [
                "Vemurafenib (Zelboraf)",
                "Dabrafenib (Tafinlar)",
                "Trametinib (Mekinist)",
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Ipilimumab (Yervoy)",
                "Cemiplimab (Libtayo)",
                "Imiquimod (Aldara)",
                "Fluorouracil (5-FU, Efudex)",
                "Sonidegib (Odomzo)",
                "Vismodegib (Erivedge)",
                "Cobimetinib (Cotellic)",
                "Encorafenib (Braftovi)",
                "Talimogene laherparepvec (T-VEC, Imlygic)",
                "Binimetinib (Mektovi)",
                "Atezolizumab (Tecentriq)",
                "Afatinib (Gilotrif)",
                "Erlotinib (Tarceva)",
                "Axitinib (Inlyta)",
                "Brentuximab vedotin (Adcetris)",
                "Selumetinib (Koselugo)",
                "Lenvatinib (Lenvima)",
                "Capmatinib (Tabrecta)",
                "Pemetrexed (Alimta)"
            ]
        }
    ],
    "anthropic.claude-3-5-sonnet-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "anthropic.claude-3-5-sonnet-v1:0",
            "response": [
                "Vemurafenib (PLX4032)",
                "Dabrafenib (GSK2118436)",
                "Encorafenib (LGX818)",
                "Trametinib (GSK1120212)",
                "Cobimetinib (GDC-0973)",
                "Binimetinib (MEK162)",
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Ipilimumab (Yervoy)",
                "Atezolizumab (Tecentriq)",
                "Avelumab (Bavencio)",
                "Cemiplimab (Libtayo)",
                "Talimogene laherparepvec (T-VEC)",
                "Aldesleukin (Proleukin)",
                "Dacarbazine (DTIC)",
                "Temozolomide (Temodar)",
                "Imatinib (Gleevec)",
                "Sonidegib (Odomzo)",
                "Vismodegib (Erivedge)",
                "Imiquimod (Aldara)",
                "Fluorouracil (5-FU)",
                "Interferon alfa-2b (Intron A)",
                "Alitretinoin (Panretin)",
                "Bexarotene (Targretin)"
            ]
        }
    ],
    "anthropic.claude-3-opus-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "anthropic.claude-3-opus-v1:0",
            "response": [
                "Aldesleukin (IL-2)",
                "Avelumab (Bavencio)",
                "Binimetinib (Mektovi)",
                "Braftovi (Encorafenib)",
                "Cemiplimab (Libtayo)",
                "Cobimetinib (Cotellic)",
                "Dabrafenib (Tafinlar)",
                "Dacarbazine",
                "Encorafenib (Braftovi)",
                "Imatinib (Gleevec)",
                "Ipilimumab (Yervoy)",
                "Mekinist (Trametinib)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Talimogene Laherparepvec (T-VEC, Imlygic)",
                "Temozolomide (Temodar)",
                "Trametinib (Mekinist)",
                "Vemurafenib (Zelboraf)"
            ]
        }
    ],
    "anthropic.claude-3-sonnet-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "anthropic.claude-3-sonnet-v1:0",
            "response": [
                "Vismodegib (VMD)",
                "Sonidegib (SDG)",
                "Ingenol mebutate",
                "Fluorouracil (5-FU)",
                "Imiquimod",
                "Diclofenac sodium",
                "Aminolevulinic acid (ALA)",
                "Methyl aminolevulinate (MAL)",
                "Efudex (5-FU)",
                "Carac (5-FU)",
                "Aldara (imiquimod)",
                "Metvixia (MAL)",
                "Levulan (ALA)",
                "Solaraze (diclofenac)",
                "Erivedge (VMD)",
                "Odomzo (SDG)",
                "Picato (ingenol mebutate)",
                "Zyclara (imiquimod)",
                "Ameluz (ALA)",
                "Aktipak (ALA)",
                "Aklief (trifarotene)",
                "Tazverik (tazemetostat)",
                "Libtayo (cemiplimab)",
                "Keytruda (pembrolizumab)"
            ]
        }
    ],
    "anthropic.claude-3-haiku-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "anthropic.claude-3-haiku-v1:0",
            "response": [
                "Vemurafenib (VEM)",
                "Dabrafenib (DAB)",
                "Trametinib (TRA)",
                "Cobimetinib (COB)",
                "Encorafenib (ENC)",
                "Binimetinib (BIN)",
                "Vismodegib (VIS)",
                "Sonidegib (SON)",
                "Cemiplimab (CEM)",
                "Pembrolizumab (PEM)",
                "Nivolumab (NIV)",
                "Ipilimumab (IPI)",
                "Atezolizumab (ATE)",
                "Avelumab (AVE)",
                "Durvalumab (DUR)",
                "Dostarlimab (DOS)",
                "Lambrolizumab (LAM)",
                "Tremelimumab (TRE)",
                "Relatlimab (REL)",
                "Spartalizumab (SPA)",
                "Tebentafusp (TEB)",
                "Bempegaldesleukin (BEM)",
                "Lifileucel (LIF)",
                "Tebentafusp-tebn (TEB-T)"
            ]
        }
    ],
    "meta.llama3-8b-instruct-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "meta.llama3-8b-instruct-v1:0",
            "response": [
                "Bexarotene (Targretin) (BEX)",
                "Aldesleukin (Proleukin)",
                "Bortezomib (Velcade)",
                "Carboplatin (Paraplatin)",
                "Cisplatin",
                "Cyclophosphamide (Cytoxan)",
                "Dacarbazine (DTIC-Dome)",
                "Doxorubicin (Adriamycin)",
                "Etoposide (VePesid)",
                "Ifosfamide (Ifex)",
                "Ixabepilone (Ixempra)",
                "Paclitaxel (Taxol)",
                "Pemetrexed (Alimta)",
                "Pralatrexate (Folotyn)",
                "Rapamycin (Sirolimus)",
                "Temsirolimus (Torisel)",
                "Thalidomide",
                "Topotecan (Hycamtin)",
                "Vemurafenib (Zelboraf)",
                "Vincristine (Oncovin)"
            ]
        }
    ],
    "meta.llama3-70b-instruct-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "meta.llama3-70b-instruct-v1:0",
            "response": [
                "Abraxane (ABR-001079)",
                "Akt inhibitor (Akt1/2)",
                "Alecensa (CH5424802)",
                "Bafetinib (INNO-406)",
                "Bexarotene (Targretin)",
                "Cabozantinib (XL184)",
                "Cetuximab (Erbitux)",
                "Cobimetinib (GDC-0973)",
                "Dabrafenib (Tafinlar)",
                "Encorafenib (LGX818)",
                "Erlotinib (Tarceva)",
                "Ibrutinib (Imbruvica)",
                "Ipilimumab (Yervoy)",
                "Lapatinib (Tykerb)",
                "Nemorazole (PD-0325901)",
                "Nivolumab (Opdivo)",
                "Olaparib (Lynparza)",
                "Pacritinib (SB1518)",
                "Pembrolizumab (Keytruda)",
                "Sonidegib (Odomzo)",
                "Sorafenib (Nexavar)",
                "Trametinib (Mekinist)",
                "Vemurafenib (Zelboraf)",
                "Vismodegib (Erivedge)"
            ]
        }
    ],
    "amazon.titan-text-express-v1": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat skin cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for skin cancer"
            },
            "model": "amazon.titan-text-express-v1",
            "response": "{\n    \"1\": \"Adalimumab\" (Humira) ,\n    \"2\": \"Alemtuzumab\" (Campath),\n    \"3\": \"Amevive\" (Alefacept),\n    \"4\": \"Amevive\" (Alefacept),\n    \"5\": \"Amevive\" (Alefacept),\n    \"6\": \"Amevive\" (Alefacept),\n    \"7\": \"Amevive\" (Alefacept),\n    \"8\": \"Amevive\" (Alefacept),\n    \"9\": \"Amevive\" (Alefacept),\n    \"10\": \"Amevive\" (Alefacept),\n    \"11\": \"Amevive\" (Alefacept),\n    \"12\": \"Amevive\" (Alefacept),\n    \"13\": \"Amevive\" (Alefacept),\n    \"14\": \"Amevive\" (Alefacept),\n    \"15\": \"Amevive\" (Alefacept),\n    \"16\": \"Amevive\" (Alefacept),\n    \"17\": \"Amevive\" (Alefacept),\n    \"18\": \"Amevive\" (Alefacept),\n    \"19\": \"Amevive\" (Alefacept),\n    \"20\": \"Amevive\" (Alefacept),\n    \"21\": \"Amevive\" (Alefacept),\n    \"22\": \"Amevive\" (Alefacept),\n    \"23\": \"Amevive\" (Alefacept),\n    \"24\": \"Amevive\" (Alefacept)\n}"
        }
    ]
}